DC-CIK细胞过继免疫治疗联合XELOX方案化疗对进展期结直肠癌患者的疗效研究  

Effect of Adoptive Immunotherapy with DC-CIK Cells Combined with XELOX Chemotherapy on Patients with Advanced Colorectal Cancer

作　　者：张静 杨光 ZHANG Jing;YANG Guang(Department of Oncology,Suzhou Benq Hospital,Suzhou,Jiangsu Province,215004 China)

机构地区：[1]苏州明基医院肿瘤科,江苏苏州215004

出　　处：《系统医学》2024年第7期31-34,共4页Systems Medicine

摘　　要：目的探讨对进展期结直肠癌患者采用树突状细胞诱导的杀伤细胞(Dendritic Cell-cytokine-induced Killer,DC-CIK)过继免疫治疗+XELOX方案化疗的临床效果。方法选取苏州明基医院于2019年2月—2022年3月收治的98例进展期结直肠癌患者为研究对象,依据投掷硬币法分为两组,各49例。参照组采取单纯化疗方法,研究组采取DC-CIK细胞过继免疫治疗+XELOX方案化疗,对比两组的治疗结果。结果治疗后,研究组疾病缓解率(63.27%)、疾病控制率(75.51%)优于参照组的40.82%、55.10%,差异有统计学意义(χ^(2)=4.947、4.503,P均<0.05);治疗后,研究组自然杀伤细胞、CD3^(+)、CD4^(+)水平高于参照组,CD8^(+)水平低于参照组,差异有统计学意义(P均<0.05);治疗后,研究组白细胞介素-2、肿瘤坏死因子-α以及干扰素-γ水平高于参照组,差异有统计学意义(P均<0.05)。结论对进展期结直肠癌患者采用DC-CIK细胞过继免疫治疗+XELOX方案化疗可获得明显的综合效果。Objective To explore the clinical effect of adoptive immunotherapy of dendritic cell-induced killer(DCCIK)cells and chemotherapy with XELOX regimen in patients with advanced colorectal cancer.Methods A total of 98 patients with advanced colorectal cancer admitted to Suzhou Benq Hospital from February 2019 to March 2022 were selected as the research objects.According to the coin tossing method,they were divided into two groups,49 cases in each group.The reference group was treated with chemotherapy alone,and the study group was treated with DC-CIK cell adoptive immunotherapy+XELOX regimen chemotherapy.The treatment results of the two groups were compared.Results After treatment,the disease remission rate(63.27%)and disease control rate(75.51%)in the study group were better than those in the reference group(40.82% and 55.10%,respectively),and the differences were statistically significant(χ^(2)=4.947,4.503,both P<0.05).After treatment,the levels of natural killer cell,CD3^(+)and CD4^(+)in the study group were higher than those in the reference group,and the level of CD8^(+)was lower than that in the reference group,and the differences were statistically significant(all P<0.05).After treatment,the levels of interleukin-2 and tumour necrosis factor-αand interferon-γin the study group were higher than those in the reference group,and the differences were statistically significant(all P<0.05).Conclusion After adopting DC-CIK cell adoptive immunotherapy plus XELOX chemotherapy for advanced colorectal cancer patients,the comprehensive effect is obvious.

关 键 词：DC-CIK细胞过继免疫 XELOX方案化疗 进展期结直肠癌 

分 类 号：R735[医药卫生—肿瘤]